Agios Pharmaceuticals Inc
(NAS:AGIO)
$
59.025
0.005 (0.01%)
Market Cap: 3.37 Bil
Enterprise Value: 2.42 Bil
PE Ratio: 5.20
PB Ratio: 2.07
GF Score: 37/100 
Agios Pharmaceuticals Inc at Leerink Global Healthcare Conference Transcript
Feb 25, 2020 / 03:30PM GMT
Release Date Price:
$46.71
(-5.96%)
Andrew Scott Berens
SVB Leerink LLC, Research Division - MD of Targeted Oncology & Senior Research Analyst
All right. Why don't we get started. I'm Andy Berens, Senior Biotech Analyst at SVB Leerink, and we're pleased to have Jackie Fouse, CEO of Agios with us.
Thank you for joining us, Jackie.
Jacqualyn A. Fouse
Agios Pharmaceuticals, Inc. - CEO & Director
Happy to be here.
Andrew Scott Berens
SVB Leerink LLC, Research Division - MD of Targeted Oncology & Senior Research Analyst
Appreciate it. I know, obviously, it's a name that a lot of people know, but maybe there's some people in the room that don't know the story. What -- can we just get a brief overview of the company before we dive in?
Jacqualyn A. Fouse
Agios Pharmaceuticals, Inc. - CEO & Director
Sure. Sounds good. So I'm going to stand up for this. I just have like 3 or 4 slides to walk people through. For those of you who are less familiar with our story, these are the forward
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers